By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
enGenes Biotech to provide ECOnti update at ICB VI continuous biomanufacturing event
Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) is returning to the 6th Integrated Continuous Biomanufacturing (ICB VI) conference in the US eastern state of Virginia to highlight its progress towards continuous manufacturing of biotech products as part of the ECOnti Project.
enGenes will show the conference how its advanced protein, enzyme, and DNA production platforms such as -eXpress™, and -eXcite™, are playing significant roles in the progress towards continuous biologics production.
Continuous biologic production
As part of the ICB VI Session: ‘Breakthrough ICB technologies on the horizon’ that commences the conference’s final working day, enGenes CEO Dr. Jürgen Mairhofer will speak on “ECOnti – Advancing Integrated Continuous Manufacturing with Microbial Cells” (Wednesday October 23, 0950-1015 hrs.). His presentation will form an update on his similarly titled report to the 2022 ICB V Conference in Spain.
PhD student Florian Simon, a researcher at enGenes within the ECOnti project, will deliver a poster on its main technologies.
Enhanced expression platforms
Both the presentation and poster will highlight the significance of enGenes’ patented -eXcite™, technology for continuous two-stage manufacturing, as well as its proven -eXpress™ platform for boosting protein expression yields in E. coli.
ICB VI will hear more on the potential of the ECOnti Project from another consortium partner, Qubicon AG, whose CEO Dr. Wolfgang Sommeregger is also attending the conference.
Greener manufacturing
Dr. Mairhofer commented: “I am excited to demonstrate how ECOnti has made substantial progress towards achieving its goals of reducing manufacturing costs and promoting a more sustainable production model. This is driven by key advantages such as space-time-yield, lower water and energy usage, a smaller carbon footprint, comprehensive end-to-end process control, and full automation through digital twin modeling.”
Qubicon is adapting its process automation and control platform to the project while other partners Tosoh Bioscience, Novasign, and SimVantage are respectively contributing expertise in continuous DSP, software for hybrid modelling, and software and expertise for CFD modelling.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes -eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes- eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
Find out more at: https://www.engenes.cc
About ICB VI
The Integrated Continuous Biomanufacturing conference series was established in 2013 in Barcelona, Spain to provide a biennial platform for an international gathering of thought leaders across industry and academia to discuss and debate the promise of integrated continuous manufacturing for biological therapeutics.
Previous ICB conferences have been held in 2015 (Berkeley, USA), 2017 (Cascais, Portugal), 2019 (Cape Cod, USA) and 2022 (Sitges, Spain).
The 6th Integrated Continuous Biomanufacturing Conference (ICB VI) will return to the USA as a five-day event opening October 20 at the Lansdowne Resort & Conference Center, in Leesburg, Virginia.
ICB VI will showcase progress towards implementation of integrated continuous biomanufacturing technologies for GMP biomanufacturing via case studies of clinical and commercial bioprocesses. Conference sessions will highlight areas related to Regulatory Affairs, Simplification, Emerging Therapeutic Modalities, Process Analytical Technology (PAT), Sustainability, as well as Modeling, Automation, and Control.
Keynote Speakers will include Dr. Peter Marks, Director, of the FDA’s Center for Biologics Evaluation and Research, and Dr. Dava Newman, Director of the Media Lab at the Massachusetts Institute of Technology (MIT).
The conference will see the ICB Inaugural Lifetime Achievement Award conferred on Professor Charles Cooney, founding Faculty Director of the Deshpande Center for Technological Innovation at MIT. Prof. Cooney an eminent scholar and innovator who has been directly engaged in the continuous biomanufacturing field since the 1960s.
The event is organized by US-based Engineering Conferences International with further information at https://engconf.us/conferences/biotechnology/integrated-continuous-biomanufacturing-vi/
ICB VI conference venue: Lansdowne Resort & Spa, Leesburg, VA.
enGenes CEO Dr. Juergen Mairhofer.
Related Articles
